Caveolin-1-deficient mice show insulin resistance and defective insulin receptor protein expression in adipose tissue

American Journal of Physiology - Cell Physiology

Volumn 285, Issue 1 54-1, 2003, Pages

  Cohen, Alex W ^a,b   Razani, Babak ^a,b   Wang, Xiao Bo ^a,b   Combs, Terry P ^a   Williams, Terence M ^a,b   Scherer, Philipp E ^a   Lisanti, Michael P ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b ALBERT EINSTEIN CANCER CENTER   (United States)

Author keywords

Caveolae; Caveolin; Insulin signaling; Knockout mice; Protein stabilization

Indexed keywords

CAVEOLIN 1; CHAPERONE; INSULIN; INSULIN RECEPTOR; MESSENGER RNA; RECEPTOR PROTEIN; RECOMBINANT PROTEIN;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FAT INTAKE; HYPERINSULINEMIA; INSULIN METABOLISM; INSULIN RESISTANCE; INSULIN TOLERANCE TEST; KNOCKOUT MOUSE; LEAN BODY WEIGHT; LIPOGENESIS; MOUSE; NONHUMAN; NULL ALLELE; PHENOTYPE; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WILD TYPE;

ANIMALIA;

EID: 0037663884     PISSN: 03636143     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpcell.00006.2003     Document Type: Article

References (50)

1. Bickel PE. Lipid rafts and insulin signaling. Am J Physiol Endocrinol Metab 282: E1-E10, 2002.
2. Blüher M, Michael MD, Peroni OD, Ueki K, Carter N, Kahn BB, and Kahn CR. Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev Cell 3: 25-38, 2002.
3. Charron MJ, Katz EB, and Olson AL. GLUT4 gene regulation and manipulation. J Biol Chem 274: 3253-3256, 1999.
4. Couet J, Sargiacomo M, and Lisanti MP. Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. J Biol Chem 272: 30429-30438, 1997.
5. Cusin I, Terrettaz J, Rohner-Jeanrenaud F, Zarjevski N, Assimacopoulos-Jeannet F, and Jeanrenaud B. Hyperinsulinemia increases the amount of GLUT4 mRNA in white adipose tissue and decreases that of muscles: a clue for increased fat depot and insulin resistance. Endocrinology 127: 3246-3248, 1990.
6. Drab M, Verkade P, Elger M, Kasper M, Lohn M, Lauterbach B, Menne J, Lindschau C, Mende F, Luft FC, Schedl A, Haller H, and Kurzchalia TV. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 293: 2449-2452, 2001.
7. Eldar-Finkelman H, Schreyer SA, Shinohara MM, LeBoeuf RC, and Krebs EG. Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6J mice. Diabetes 48: 1662-1666, 1999.
8. Friedman J. Fat in all the wrong places. Nature 415: 268-269, 2002.
9. Imamura T, Haruta T, Takata Y, Usui I, Iwata M, Ishihara H, Ishiki M, Ishibashi O, Ueno E, Sasaoka T, and Kobayashi M. Involvement of heat shock protein 90 in the degradation of mutant insulin receptors by the proteasome. J Biol Chem 273: 11183-11188, 1998.
10. Imamura T, Takata Y, Sasaoka T, Takada Y, Morioka H, Haruta T, Sawa T, Iwanishi M, Hu YG, Suzuki Y, Hamada J, and Kobayashi M. Two naturally occurring mutations in the kinase domain of insulin receptor accelerate degradation of the insulin receptor and impair the kinase activity. J Biol Chem 269: 31019-31027, 1994.
11. Iverson SJ, Lang SL, and Cooper MH. Comparison of the Bligh and Dyer and Folch methods for total lipid determination in a broad range of marine tissue. Lipids 36: 1283-1287, 2001.
12. Iwanishi M, Haruta T, Takata Y, Ishibashi O, Sasaoka T, Egawa K, Imamura T, Naitou K, Itazu T, and Kobayashi M. A mutation (Trp1193→Leu1193) in the tyrosine kinase domain of the insulin receptor associated with type A syndrome of insulin resistance. Diabetologia 36: 414-422, 1993.
13. Kersten S. Mechanisms of nutritional and hormonal regulation of lipogenesis. EMBO Rep 2: 282-286, 2001.
14. Lauro D, Kido Y, Castle AL, Zarnowski MJ, Hayashi H, Ebina Y, and Accili D. Impaired glucose tolerance in mice with a targeted impairment of insulin action in muscle and adipose tissue. Nat Genet 20: 294-298, 1998.
15. Liu J, Wang XB, Park DS, and Lisanti MP. Caveolin-1 expression enhances endothelial capillary tubule formation. J Biol Chem 277: 10661-10668, 2002.
16. Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Muller C, Carling D, and Kahn BB. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415: 339-343, 2002.
17. Moller DE, Benecke H, and Flier JS. Biologic activities of naturally occurring human insulin receptor mutations. Evidence that metabolic effects of insulin can be mediated by a kinase-deficient insulin receptor mutant. J Biol Chem 266: 10995-11001, 1991.
18. Moller DE, Yokota A, Ginsberg-Fellner F, and Flier JS. Functional properties of a naturally occurring Trp1200-Ser1200 mutation of the insulin receptor. Mol Endocrinol 4: 1183-1191, 1990.
19. Mora A, Sabio G, Risco AM, Cuenda A, Alonso JC, Soler G, and Centeno F. Lithium blocks the PKB and GSK3 dephosphorylation induced by ceramide through protein phosphatase-2A. Cell Signal 14: 557-562, 2002.
20. Nakae J, Kido Y, and Accili D. Distinct and overlapping functions of insulin and IGF-I receptors. Endocr Rev 22: 818-835, 2001.
21. Nystrom FH, Chen H, Cong LN, Li Y, and Quon MJ. Caveolin-1 interacts with the insulin receptor and can differentially modulate insulin signaling in transfected Cos-7 cells and rat adipose cells. Mol Endocrinol 13: 2013-2024, 1999.
22. Okamoto T, Schlegel A, Scherer PE, and Lisanti MP. Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane. J Biol Chem 273: 5419-5422, 1998.
23. Palade GE. Fine structure of blood capillaries (Abstract). J Appl Physiol 24: 1424, 1953.
24. Parolini I, Sargiacomo M, Galbiati F, Rizzo G, Grignani F, Engelman JA, Okamoto T, Ikezu T, Scherer PE, Mora R, Rodriguez-Boulan E, Peschle C, and Lisanti MP. Expression of caveolin-1 is required for the transport of caveolin-2 to the plasma membrane. Retention of caveolin-2 at the level of the Golgi complex. J Biol Chem 274: 25718-25725, 1999.
25. Parpal S, Karlsson M, Thorn H, and Stralfors P. Cholesterol depletion disrupts caveolae and insulin receptor signaling for metabolic control via insulin receptor substrate-1, but not for mitogen-activated protein kinase control. J Biol Chem 276: 9670-9678, 2001.
26. Podar K, Tai YT, Cole CE, Hideshima T, Sattler M, Hamblin A, Mitsiades N, Schlossman RL, Davies FE, Morgan GJ, Munshi NC, Chauhan D, and Anderson KC. Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells. J Biol Chem 278: 5794-5801, 2003.
27. Razani B, Combs TP, Wang XB, Frank PG, Park DS, Russell RG, Li M, Tang B, Jelicks LA, Scherer PE, and Lisanti MP. Caveolin-1 deficient mice are lean, resistant to diet-induced obesity, and show hyper-triglyceridemia with adipocyte abnormalities. J Biol Chem 277: 8635-8647, 2001.
28. Razani B, Engelman JA, Wang XB, Schubert W, Zhang XL, Marks CB, Macaluso F, Russell RG, Li M, Pestell RG, Di Vizio D, Hou H Jr, Kneitz B, Lagaud G, Christ GJ, Edelmann W, and Lisanti MP. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem 276: 38121-38138, 2001.
29. Razani B and Lisanti MP. Caveolin-deficient mice: insights into caveolar function and human disease. J Clin Invest 108: 1553-1561, 2001.
30. Razani B, Rubin CS, and Lisanti MP. Regulation of cAMP-mediated signal transduction via interaction of caveolins with the catalytic subunit of protein kinase A. J Biol Chem 274: 26353-26360, 1999.
31. Razani B, Wang XB, Engelman JA, Battista M, Lagaud G, Zhang XL, Kneitz B, Hou H Jr, Christ GJ, Edelmann W, and Lisanti MP. Caveolin-2-deficient mice show evidence of severe pulmonary dysfunction without disruption of caveolae. Mol Cell Biol 22: 2329-2344, 2002.
32. Rothberg KG, Heuser JE, Donzell WC, Ying Y, Glenney JR, and Anderson RGW. Caveolin, a protein component of caveolae membrane coats. Cell 68: 673-682, 1992.
33. Saltiel AR and Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414: 799-806, 2001.
34. Saltiel AR and Pessin JE. Insulin signaling pathways in time and space. Trends Cell Biol 12: 65-71, 2002.
35. Sawa T, Imamura T, Haruta T, Sasaoka T, Ishiki M, Takata Y, Takada Y, Morioka H, Ishihara H, Usui I, and Kobayashi M. Hsp70 family molecular chaperones and mutant insulin receptor: differential binding specificities of BiP and Hsp70/Hsc70 determines accumulation or degradation of insulin receptor. Biochem Biophys Res Commun 218: 449-453, 1996.
36. Scherer PE, Lewis RY, Volonte D, Engelman JA, Galbiati F, Couet J, Kohtz DS, van Donselaar E, Peters P, and Lisanti MP. Cell-type and tissue-specific expression of caveolin-2. Caveolins 1 and 2 co-localize and form a stable heterooligomeric complex in vivo. J Biol Chem 272: 29337-29346, 1997.
37. Scherer PE, Okamoto T, Chun M, Nishimoto I, Lodish HF, and Lisanti MP. Identification, sequence and expression of caveolin-2 defines a caveolin gene family. Proc Natl Acad Sci USA 93: 131-135, 1996.
38. Scherer PE, Tang ZL, Chun MC, Sargiacomo M, Lodish HF, and Lisanti MP. Caveolin isoforms differ in their N-terminal protein sequence and subcellular distribution: identification and epitope mapping of an isoform-specific monoclonal antibody probe. J Biol Chem 270: 16395-16401, 1995.
39. Shigematsu S, Watson RT, Khan AH, and Pessin JE. The adipocyte plasma membrane caveolin functional/structural organization is necessary for the efficient endocytosis of GLUT4. J Biol Chem 278: 10683-10690, 2002.
40. Shimaya A, Noshiro O, Hirayama R, Yoneta T, Niigata K, and Shikama H. Insulin sensitizer YM268 ameliorates insulin resistance by normalizing the decreased content of GLUT4 in adipose tissue of obese Zucker rats. Eur J Endocrinol 137: 693-700, 1997.
41. Shimomura I, Hammer RE, Ikemoto S, Brown MS, and Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 401: 73-76, 1999.
42. Sotgia F, Razani B, Bonuccelli G, Schubert W, Battista M, Lee H, Capozza F, Schubert AL, Minetti C, Buckley JT, and Lisanti MP. Intracellular retention of GPI-linked proteins in caveolin-deficient cells. Mol Cell Biol 22: 3905-3926, 2002.
43. Syu LJ and Saltiel AR. Lipotransin: a novel docking protein for hormone-sensitive lipase. Mol Cell 4: 109-115, 1999.
44. Tang ZL, Scherer PE, Okamoto T, Song K, Chu C, Kohtz DS, Nishimoto I, Lodish HF, and Lisanti MP. Molecular cloning of caveolin-3, a novel member of the caveolin gene family expressed predominantly in muscle. J Biol Chem 271: 2255-2261, 1996.
45. Toya Y, Yamamoto M, Schwencke C, Lisanti MP, Myers M, and Ishikawa Y. Caveolin is an activator of insulin receptor signaling. J Biol Chem 273: 26962-26968, 1998.
46. Watson RT and Pessin JE. Subcellular compartmentalization and trafficking of the insulin-responsive glucose transporter, GLUT4. Exp Cell Res 271: 75-83, 2001.
47. Wijkander J, Landstrom TR, Manganiello V, Belfrage P, and Degerman E. Insulin-induced phosphorylation and activation of phosphodiesterase 3B in rat adipocytes: possible role for protein kinase B but not mitogen-activated protein kinase or p70 S6 kinase. Endocrinology 139: 219-227, 1998.
48. Yamada E. The fine structure of the gall bladder epithelium of the mouse. J Biophys Biochem Cytol 1: 445-458, 1955.
49. Yamamoto M, Toya Y, Schwencke C, Lisanti MP, Myers M, and Ishikawa Y. Caveolin is an activator of insulin receptor signaling. J Biol Chem 273: 26962-26968, 1998.
50. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, and Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7: 941-946, 2001.